Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study-Reference-Cited by-同舟云学术

Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study

Published:2024-01 Issue:1 Volume:24 Page:55-63
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Gordan Lucio Navarro,Tan Carlyn Rose,Vescio Robert,Ye Jing Christine,Schinke Carolina,Medhekar Rohan,Fu Alex Z.,Lafeuille Marie-Hélène,Thompson-Leduc Philippe^ORCID,Khare Vipin,Reitan John,Milkovich Gary,Kaila Shuchita,Davies Faith,Usmani Saad Z.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference30 articles.

1. Multiple myeloma;Kumar;Nat Rev Dis Primers,2017

2. Cancer statistics, 2023;Siegel;CA Cancer J Clin,2023

3. Surveillance Epidemiology and End Results (SEER) Program. Cancer stat facts: myeloma;SEER,2023

4. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(dagger);Dimopoulos;Ann Oncol,2021

5. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation;Palumbo;J Clin Oncol,2014

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data;Advances in Therapy;2024-03-18